Welcome to HitGen

News

Get up to date with the latest HitGen articles and join us in the events

  1. News
  2. Press Release

Press Release

  • 02 September 2021
    Veritas In Silico and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based RNA-targeting small molecule Drug Discovery
    CHENGDU, China, Sep 2nd, 2021-- Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) and Veritas In Silico Inc. (“Veritas In Silico”), a Tokyo-based private company, today announced that they have entered into a research collaboration agreement to discover small molecule compounds against RNA targets. Veritas In Silico will apply its drug discovery platform, ibVIS, to identify certain RNA targets that are of interest to Veritas In Silico.
  • 31 August 2021
    Infographic | HitGen FY2021 Mid-term Report
    HitGen FY2021 Mid-term Report
  • 10 June 2021
    Vernalis, a fully owned subsidiary of HitGen Inc., and Servier achieve two milestones in their oncology drug discovery collaboration
    Chengdu, China, 10 June 2021 – Vernalis, a fully owned subsidiary of HitGen Inc., and Servier are pleased to announce the achievement of one research and one pre-clinical milestone in their oncology drug discovery collaboration, triggering undisclosed milestone payments to Vernalis.
  • 27 May 2021
    Available now! Whitepaper: Advancing Drug Discovery through DNA Encoded Library Technology!
    CHENGDU, China, May 27th, 2021 HitGen and Fierce Biotech jointly release the Whitepaper: Advancing Drug Discovery through DNA-Encoded Library (DEL) Technology today. This whitepaper will provide the drug discovery community with an in depth dive of DEL technology and stimulate innovation in the field by describing HitGen’s experiences and knowledges on DEL design, synthesis, screening and expanded applications.
  • 24 May 2021
    Dorian and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
    CHENGDU, China, May 24th, 2021-- Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Dorian Therapeutics, Inc.
  • 13 May 2021
    Coming Soon! Whitepaper: Advancing Drug Discovery through DNA-Encoded Library Technology!
    Since its concept was conceived in 1992, DNA-encoded chemical libraries (DELs) have evolved into a valuable technology for hit identification in drug discovery.
  • 06 April 2021
    HitGen and BioAge Announce Research Progress in DNA-Encoded Library Based Drug Discovery Research Collaboration
    On 6th April 2021, CHENGDU, China-- Shanghai Stock Exchange listed biotech company HitGen Inc. (“HitGen”) announced important research progress in a collaboration with BioAge Labs, Inc. (“BioAge”), a private biotechnology company developing targeted small molecules for the treatment of diseases of aging. The companies have conducted collaborative research to identify and develop novel small-molecule compounds against a high-value and challenging biological target that is a critical component of the innate immune system. Dysregulation of this target is closely linked to the underlying cause of severe diseases in elderly humans, such as Alzheimer's and cardiovascular disease.
  • 10 March 2021
    Lipigon expands collaboration with HitGen by selecting second target
    Chengdu, China March 10th, 2021 Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, today announced that the company has expanded its agreement with the Shanghai STAR listed company HitGen Inc. (”HitGen”) to include a second novel target. With joint efforts, the aim is to develop a treatment for cardiometabolic disease.
  • 01 March 2021
    HitGen and UPPTHERA Enter Into Drug Discovery Research Collaboration
    CHENGDU, China, March 1st, 2021 -- HitGen (688222.SH) today announced that it has entered into a drug discovery research collaboration with UPPTHERA Inc. to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase. HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets. The identified compounds will be exclusively licensed to UPPTHERA for further development. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment, success fee, license/milestone fee from UPPTHERA.
  • 21 December 2020
    HitGen announces License Agreement with Merck & Co., Inc., Kenilworth, NJ USA to access compounds for potential development of a novel class of drugs
    Chengdu, CHINA, December 21th 2020 HitGen Inc. is pleased to announce that HitGen and Merck & Co., Inc., Kenilworth, NJ USA, known as MSD outside the United States and Canada, expand their collaboration with a license to develop a novel class of drugs for an early target of high interest.

Questions?

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information